InsidersTradesSigma
Follow the 力生制药 share price and the full directors' dealings record of the company, a publicly traded company based in China. Shares are listed on the CN market, under the oversight of SSE / SZSE (CSRC). The latest transaction was reported on 4 August 2026 (Purchase). Among the most active insiders: 郭晓燕. The full history is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
力生制药是一家专注于中国药品研发和制造的公司。它专注于治疗各种疾病和医疗状况。